NUBEQA EXTENDED OVERALL SURVIVAL BY LOWERING THE RISK OF DEATH
*Hormone therapy includes drug treatments or surgery to lower testosterone.
†The clinical study in nmCRPC was designed to measure metastasis-free survival (MFS) and also overall survival.
In the clinical study for mHSPC
NUBEQA extended overall survival (32% reduction in risk of death)
More men who added NUBEQA to hormone therapy + chemotherapy were still alive at
4 years vs hormone therapy + chemotherapy alone (63% vs 50%, respectively)
In the clinical study for nmCRPC
without cancer spreading to
other parts of their body (MFS) when they added NUBEQA to hormone therapy compared with men on hormone therapy alone
(median‡ 3.4 yrs vs 1.5 yrs)
‡Median is the middle value in a set of numbers, not the average.
Press to hear pronunciation
NUBEQA Patient Brochures
Find out more about what NUBEQA can offer.
NUBEQA Side Effects
See possible side effects while taking NUBEQA.
Explore Financial Support
Plus more with Access Services by BayerTM.
Meet Dick and Jan
Learn about their journey with non-metastatic castration-resistant prostate cancer (nmCRPC) and what NUBEQA has meant to them.